Patent · US Expired

Drug therapy for Celiac Sprue

US7265093B2 · kind B2 · utility

21Cited by

6References

10Claims

0Family size

Assignee

The Board of Trustees of the Leland Stanford Junior University · US

Inventors

Chaitan Khosla · Palo Alto, US
Kihang Choi · Seoul, KR

Key dates

Filing date	Nov 18, 2003
Grant date	Sep 4, 2007
Priority date	—
Expiry date	Feb 16, 2025

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Administering an effective dose of a tTGase inhibitor to a Celiac or dermatitis herpetiformis patient reduces the toxic effects of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.